$ACAD SEC Filings

As previously disclosed in our Current Report on Form 8-K filed with the Securities and Exchange Commission on May 1, 2026, on April 27, 2026, Elizabeth H.Z. Thompson, Ph.D., Executive Vice President, Head of Research and Development of ...

Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)

This Stipulation and Agreement of Settlement (the “Stipulation”) dated July 9, 2026, is entered into by and among the following Parties (defined herein) by and through their respective counsel:

Received 5,849 shares by exercise or conversion ($104K) · Sold 5,849 shares ($170K) · Received 14,292 shares by exercise or conversion ($255K) · 1 more

Received 32,272 shares by exercise or conversion · Sold 16,558 shares ($433K)

Sold 11,421 shares ($298K)

Received 37,244 shares as a grant or award · Granted 64,016 Non- Qualified Stock Option (right to buy)

Received 8,107 shares by exercise or conversion · Granted 16,004 Director Stock Options (Right to Buy) · Granted 9,311 Restricted Stock Units

Received 8,107 shares by exercise or conversion · Granted 16,004 Director Stock Options (Right to Buy) · Granted 9,311 Restricted Stock Units

Received 8,107 shares by exercise or conversion · Granted 16,004 Director Stock Options (Right to Buy) · Granted 9,311 Restricted Stock Units

Received 2,010 shares by exercise or conversion · Granted 16,004 Director Stock Options (Right to Buy) · Granted 9,311 Restricted Stock Units

Received 8,107 shares by exercise or conversion · Granted 16,004 Director Stock Options (Right to Buy) · Granted 9,311 Restricted Stock Units

Received 8,107 shares by exercise or conversion · Granted 16,004 Director Stock Options (Right to Buy) · Granted 9,311 Restricted Stock Units